Chimeric Therapeutics
Sydney, Australia· Est.
Australian cell‑therapy pioneer advancing CAR‑T and NK‑cell cancer treatments in early clinical trials.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Australian cell‑therapy pioneer advancing CAR‑T and NK‑cell cancer treatments in early clinical trials.
Oncology
Technology Platform
Autologous CAR‑T cell engineering and allogeneic NK‑cell platforms for targeted cancer therapy, combining personalized and off‑the‑shelf approaches.
Opportunities
First‑in‑class CAR‑T targeting CDH17 and a novel scorpion‑derived CAR, plus an off‑the‑shelf NK platform, position the company to capture market share in solid‑tumor and hematologic cell‑therapy segments.
Risk Factors
Early‑stage clinical data uncertainty, manufacturing scale‑up challenges, and intense competition from established CAR‑T and NK‑cell developers.
Competitive Landscape
Competes with CAR‑T leaders (Kite, Novartis, Juno) and NK‑cell innovators (Fate Therapeutics, Nkarta), differentiating through unique antigens and a dual autologous/allogeneic approach.